Clinical Advances in Liver, Pancreas, and Biliary TractThe Natural History of Serum Iron Indices for HFE C282Y Homozygosity Associated With Hereditary Hemochromatosis
Section snippets
Patients and Methods
The present study, known as HealthIron, is a substudy of the Melbourne Collaborative Cohort Study (MCCS17). Between 1990 and 1994, 41,528 people (24,479 females) in the target age range of 40–69 years were enrolled in the MCCS. Participants were recruited via the electoral roll (voting is compulsory in Australia), advertisements, and community announcements in local media. All participants gave a blood sample at baseline. For most participants, blood spots were aliquotted onto Guthrie cards;
Features of C282Y Homozygotes
A total of 203 C282Y homozygotes (95 males, 108 females) were identified in this cohort of 31,192 people of northern European extraction. Of these, 146 (72%) participated in the follow-up, and 143 provided blood samples that yielded at least one SF or TS measurement at baseline or follow-up (Table 1). The average time between the baseline and follow-up visits was 12.0 years (range, 9.8–14.3 years).
The average age of C282Y homozygotes at baseline was 53.5 years (SD, 8.9) for males and 54.9 years
Discussion
We have studied the natural history of SF and TS measurements over a mean period of 12 years for a sample of C282Y homozygotes who are participating in a large prospective cohort study. The majority of male C282Y homozygotes (84%) had elevated SF values at baseline (mean age, 55 years) and more than one third had SF >1000 μg/L, suggesting that a substantial proportion of male C282Y homozygotes had developed significant iron loading by this age. A similar high prevalence was observed at
References (30)
Hemochromatosis: the impact of early diagnosis and therapy
Gastroenterology
(1996)- et al.
Estimates of iron sufficiency in the US population
Blood
(1986) - et al.
Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis
Gastroenterology
(1998) Is there a threshold of hepatic iron concentration that leads to cirrhosis in C282Y hemochromatosis?
Am J Gastroenterol
(2001)Diagnosis and management of hemochromatosis
Hepatology
(2001)Hemochromatosis: diagnosis and management
Gastroenterology
(2001)- et al.
Hemochromatosis mutations in the general population: iron overload progression rate
Blood
(2004) - et al.
Evolution of untreated hereditary hemochromatosis in the Busselton population: a 17-year study
Mayo Clin Proc
(2004) - et al.
Use of community genetic screening to prevent HFE-associated hereditary haemochromatosis
Lancet
(2005) - et al.
Penetrance of 845G>A (C282Y) HFE hereditary haemochromatosis mutation in the USA
Lancet
(2002)
Natural history of the C282Y homozygote for the hemochromatosis gene (HFE) with a normal serum ferritin level
Clin Gastroenterol Hepatol
Reference centiles for serum ferritin and percentage of transferrin saturation, with application to mutations of the HFE gene
Clin Chem
Iron-overload-related disease in HFE hereditary hemochromatosis
N Engl J Med
Serum ferritin level predicts advanced hepatic fibrosis among US patients with phenotypic hemochromatosis
Ann Intern Med
Screening for hemochromatosis in asymptomatic subjects with or without a family history
Arch Intern Med
Cited by (74)
Retrospective analyses of factors influencing arrhythmias and the impact of arrhythmias on inpatient outcomes among hospitalized patients with hemochromatosis
2022, International Journal of CardiologyShould we treat individuals homozygous for HFE p.Cys282Tyr with ferritin 300–1000 μg/L?
2017, The Lancet HaematologyA Mouse Model of Cardiomyopathy Induced by Mutations in the Hemochromatosis HFE Gene
2017, Canadian Journal of CardiologyHow should hyperferritinaemia be investigated and managed?
2016, European Journal of Internal MedicineHaemochromatosis
2016, The Lancet
The HealthIron Study Investigators also include Melanie Bahlo (The Walter & Eliza Hall Institute for Medical Research, Melbourne, Australia), Amanda Nicoll (Royal Melbourne Hospital, Melbourne, Australia), Amy Nisselle (Murdoch Childrens Research Institute, Melbourne, Australia), and Chris Vulpe (University of California, Berkeley, California).
The authors disclose the following: Supported by the National Institute of Diabetes, Digestive and Kidney Diseases (US) (1 RO1 DK061885-01 A2); National Health and Medical Research Council (NHMRC) (Australia) (project grant number 251668); by VicHealth and The Cancer Council Victoria for cohort recruitment; The Cancer Council Victoria and the NHMRC (program grant 209057, enabling grant 396414) for continuing follow-up; and by NHMRC Career Development Award (to L.C.G. and K.J.A), NHMRC Practitioner Fellowship (to M.B.D. and J.K.O), NHMRC Senior Research Fellowship (to M.C.S and G.J.A.), and NHMRC Australia Fellowship (to J.L.H.).